# US 6,723,740 B2 · Activator of PPAR delta

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,723,740 B2
- Document ID: US6723740B2
- Status: Granted
- Kind: B2
- Application number: 10/383,011
- Filed: 2003-03-06
- Published: 2003-10-30
- Granted: 2004-04-20
- Earliest claimed: 1999-06-25
- Assignees: SmithKline Beecham Corporation
- Inventors: Esther Yu-Hsuan Chao; Curt Dale Haffner; Millard Hurst Lambert, III; Patrick Reed Maloney; Michael Lawrence Sierra; Daniel David Sternbach; Marcos Luis Sznaidman; Timothy Mark Willson; Huaqiang Eric Xu
- Web page: https://patentgrep.com/patent/US6723740B2

## CPC

- C07D 277/26: Radicals substituted by sulfur atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 277/24: Radicals substituted by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula (I) are disclosed. These compounds selected activators of human PPAR delta.

## Claims

### Claim 1

A method for lowering triglycerides in a subject comprising the administration of a therapeutic amount of a hPPAR delta agonist of Formula (I)
wherein
X represents a COOH (or a hydrolysable ester thereof);
X1 is O or S;
X2 represents O or S;
R1 and R2 independently represent H, CH3, OCH3, or halogen,
n is 1 or 2,
one of Y and Z is N and the other is S or O;
y represents 1 or 2;
each R3 independently represents CF3 or halogen.